Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial

Clinical Infectious Diseases

Volumn 38, Issue 2, 2004, Pages 284-288

  MacArthur, Rodger D ^a,f   Miller, Mark ^d   Albertson, Timothy ^c   Panacek, Edward ^c   Johnson, David ^e   Teoh, Leah ^b   Barchuk, William ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e ROYAL UNIVERSITY HOSPITAL   (Canada)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMPIRICISM; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEPSIS; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

EID: 1642456548     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/379825     Document Type: Article

References (16)

1. Goldhill DR, Sumner A. Outcome of intensive care patients in a group of British intensive care units. Crit Care Med 1998; 26:1337-45.
2. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274:968-74.
3. Roberts F, Geere I, Coldman A. A three-year study of positive blood cultures, with emphasis on prognosis. Rev Infect Dis 1991; 13:34-46.
4. McGowan JJ, Barnes M, Finland M. Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. I Infect Dis 1975; 132: 316-35.
5. Elhanan G, Raz R, Pitlik S, et al. Bacteraemia in a community and a university hospital. J Antimicrob Chemother 1995; 36:681-95.
6. Smith R, Meixler S, Simberkoff M. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest 1991; 100: 164-7.
7. Panacek E, Marshall JC, Fischkoff S, et al. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: results of the MONARCS trial. Chest 2000; 118: 88S.
8. Bone R, Fisher CJ, Clemmer T, Slotman G, Metz C, Balk R. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17:389-93.
9. Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik S. Long-term survival following bacteremia or fungemia. JAMA 1995; 274:807-12.
10. Meyers B, Sherman E, Mendelson M, et al. Bloodstream infections in the elderly. Am J Med 1989; 86:379-84.
11. Behrendt G, Schneider S, Brodt H, G J-N, Shah P. Influence of antimicrobial treatment on mortality in septicemia. J Chemother 1999; 11:179-86.
12. Byl B, Clevenbergh P, Jacobs F, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60-6.
13. Weinstein M, Towns M, Quartey S, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584-602.
14. Leibovici L, Drucker M, Konigsberger H, et al. Septic shock in bacteremic patients: risk factors, features and prognosis. Scand J Infect Dis 1997; 29:71-5.
15. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-86.
16. Lorian V, ed. Antibiotics in laboratory medicine. 4th ed. Baltimore, MD: Williams and Wilkins, 1996.